Prostate cancer Board decisions

The Veteran's claims for increased ratings and TDIU are being remanded due to the need for additional medical records, including VA treatment records and private medical records from Penn Medicine and Pennsylvania Hospital.

The Board has remanded the Veteran's claims for service connection for obstructive sleep apnea and prostate cancer due to inadequate VA opinions. The Veteran is also seeking an earlier effective date for his combined service-connected disability rating of 60 percent, which is pending resolution of these issues.

The Board has granted service connection for prostate cancer, voiding dysfunction as secondary to prostate cancer, and scars as secondary to prostate cancer. The Veteran's claim for mood disorder associated with his prostate cancer is remanded due to the need for a medical examination.

The Veteran's appeals for earlier effective dates for prostate cancer and Type II Diabetes Mellitus have been dismissed. The appeal regarding a higher rating for prostate cancer from prior to March 1, 2020 is remanded. The appeal regarding a higher rating for DM is also remanded.

The Veteran's claim for a higher disability rating for prostate cancer residuals from January 1, 2016 is denied as the reduction in his evaluation was proper and he does not meet the criteria for a higher rating.

The Board has granted an effective date of August 1, 2010 for the grant of service connection for PTSD and prostate cancer.

The Veteran's claim for service connection for a fractured jaw has been denied as there is no evidence of current residuals or any history of such condition during the pendency of his claim.,His claims for service connection for prostate cancer, hypertension, bruxism, and disability of the jaw other than jaw fracture are remanded due to incomplete service records and potential exposure to herbicide agents.

The Veteran's service-connected disabilities do not preclude him from securing or following a substantially gainful occupation, and the Board finds that his TDIU claim has not met the schedular requirements for a TDIU rating.

The Veteran's appeal was dismissed due to his death, and the Board has no jurisdiction to adjudicate the merits of this appeal at this time.

The Board has granted service connection for prostate cancer, finding that the Veteran's military duties placed him at or near the perimeter of U-Tapao RTAFB in Thailand during his Vietnam-era service. The disability is presumed to have been incurred due to exposure to herbicide agents used in support of military operations.

The Veteran's appeal involves the discontinuance of a 100 percent rating for prostate cancer effective September 30, 2018, and a disability rating in excess of 40 percent for prostate cancer effective from October 1, 2018. The Board has ordered additional medical records to be obtained as they are relevant to assessing the Veteran's condition.

The Board has granted service connection for a genital skin disorder as secondary to the Veteran's service-connected prostate cancer. The reduction in the rating assigned for prostate cancer from 100 percent to 60 percent, effective December 1, 2019, is denied.

The Veteran's prostate cancer was denied service connection due to lack of evidence linking it to service. The initial rating for left eye chorioretinal scars and cataract is granted at 10%, but a higher rating is denied. A separate 10% rating is granted for dry eye syndrome.

The Board dismissed the appeals for service connection for diabetes mellitus type II and prostate cancer, both secondary to exposure to herbicide agents.

The Veteran's diabetes mellitus type II, Parkinson's disease, prostate cancer, and erectile dysfunction (ED) are all granted service connection as due to herbicide exposure in Vietnam.

The Board denied service connection for heart disease and residuals of prostate cancer as there was no evidence of herbicide exposure during service, and the Veteran did not have a current disability related to his in-service duties.

The Veteran's effective date for additional compensation for his children L.B. and A.B., as dependents, is granted to March 10, 2011, the date he was first rated 30% or more disabled.

The Board found that the discontinuation of the 100 percent rating for prostate cancer effective October 1, 2021 was proper based on the cessation of treatment and VA's compliance with all requirements under Diagnostic Code 7528.

The Veteran's prostate cancer residuals are rated at 40% effective January 1, 2020. His erectile dysfunction is granted a 20% rating. Service connection has been established for bilateral atrophy of the testes and gynecomastia.

Your appeals for prostate cancer service connection and nonservice connected pension have been dismissed as the appellant has withdrawn them.